- Home
- VSTM vs RZLT Comparison
VSTM vs RZLT Comparison
Compare VSTM & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- RZLT
- Stock Information
- Founded
- VSTM 2010
- RZLT 2010
- Country
- VSTM United States
- RZLT United States
- Employees
- VSTM N/A
- RZLT N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- RZLT Health Care
- Exchange
- VSTM Nasdaq
- RZLT Nasdaq
- Market Cap
- VSTM 345.6M
- RZLT 361.3M
- IPO Year
- VSTM 2012
- RZLT N/A
- Fundamental
- Price
- VSTM $8.23
- RZLT $6.50
- Analyst Decision
- VSTM Strong Buy
- RZLT Strong Buy
- Analyst Count
- VSTM 9
- RZLT 5
- Target Price
- VSTM $12.75
- RZLT $12.50
- AVG Volume (30 Days)
- VSTM 3.1M
- RZLT 853.0K
- Earning Date
- VSTM 08-07-2025
- RZLT 09-18-2025
- Dividend Yield
- VSTM N/A
- RZLT N/A
- EPS Growth
- VSTM N/A
- RZLT N/A
- EPS
- VSTM N/A
- RZLT N/A
- Revenue
- VSTM $2,137,000.00
- RZLT N/A
- Revenue This Year
- VSTM $55.63
- RZLT N/A
- Revenue Next Year
- VSTM $453.72
- RZLT N/A
- P/E Ratio
- VSTM N/A
- RZLT N/A
- Revenue Growth
- VSTM N/A
- RZLT N/A
- 52 Week Low
- VSTM $2.24
- RZLT $2.22
- 52 Week High
- VSTM $9.10
- RZLT $6.65
- Technical
- Relative Strength Index (RSI)
- VSTM 73.06
- RZLT 70.63
- Support Level
- VSTM $7.44
- RZLT $5.52
- Resistance Level
- VSTM $8.76
- RZLT $6.61
- Average True Range (ATR)
- VSTM 0.64
- RZLT 0.30
- MACD
- VSTM 0.23
- RZLT 0.02
- Stochastic Oscillator
- VSTM 84.05
- RZLT 89.91
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.